Assessment of EPS and tardive dyskinesia in clinical trials

Herbert Y. Meltzer*

*Corresponding author for this work

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

The incidence of acute extrapyramidal symptoms (EPS) - akathisia, dystonia, and parkinsonism - associated with traditional antipsychotics varies, but most researchers agree that neuroleptic-induced EPS occur in 50% to 75% of patients who take conventional antipsychotics. Atypical antipsychotics were developed to widen the therapeutic index and to reduce EPS. Although the mechanisms are unclear, the risk of EPS is less with the novel antipsychotics than with conventional drugs, and agents that produce low levels of acute EPS are likely to produce less tardive dyskinesia. Nevertheless, clinicians should exercise caution when comparing data from investigations of the novel antipsychotics and, until long-term data become available, should administer the new drags at doses below the EPS-producing level.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalJournal of Clinical Psychiatry
Volume59
Issue numberSUPPL. 12
StatePublished - Oct 5 1998

Fingerprint

Symptom Assessment
Antipsychotic Agents
Clinical Trials
Psychomotor Agitation
Dystonia
Parkinsonian Disorders
Tardive Dyskinesia
Research Personnel
Exercise
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

@article{19b5ee5e24e14a919d873fb9a4f350c0,
title = "Assessment of EPS and tardive dyskinesia in clinical trials",
abstract = "The incidence of acute extrapyramidal symptoms (EPS) - akathisia, dystonia, and parkinsonism - associated with traditional antipsychotics varies, but most researchers agree that neuroleptic-induced EPS occur in 50{\%} to 75{\%} of patients who take conventional antipsychotics. Atypical antipsychotics were developed to widen the therapeutic index and to reduce EPS. Although the mechanisms are unclear, the risk of EPS is less with the novel antipsychotics than with conventional drugs, and agents that produce low levels of acute EPS are likely to produce less tardive dyskinesia. Nevertheless, clinicians should exercise caution when comparing data from investigations of the novel antipsychotics and, until long-term data become available, should administer the new drags at doses below the EPS-producing level.",
author = "Meltzer, {Herbert Y.}",
year = "1998",
month = "10",
day = "5",
language = "English (US)",
volume = "59",
pages = "23--27",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 12",

}

Assessment of EPS and tardive dyskinesia in clinical trials. / Meltzer, Herbert Y.

In: Journal of Clinical Psychiatry, Vol. 59, No. SUPPL. 12, 05.10.1998, p. 23-27.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Assessment of EPS and tardive dyskinesia in clinical trials

AU - Meltzer, Herbert Y.

PY - 1998/10/5

Y1 - 1998/10/5

N2 - The incidence of acute extrapyramidal symptoms (EPS) - akathisia, dystonia, and parkinsonism - associated with traditional antipsychotics varies, but most researchers agree that neuroleptic-induced EPS occur in 50% to 75% of patients who take conventional antipsychotics. Atypical antipsychotics were developed to widen the therapeutic index and to reduce EPS. Although the mechanisms are unclear, the risk of EPS is less with the novel antipsychotics than with conventional drugs, and agents that produce low levels of acute EPS are likely to produce less tardive dyskinesia. Nevertheless, clinicians should exercise caution when comparing data from investigations of the novel antipsychotics and, until long-term data become available, should administer the new drags at doses below the EPS-producing level.

AB - The incidence of acute extrapyramidal symptoms (EPS) - akathisia, dystonia, and parkinsonism - associated with traditional antipsychotics varies, but most researchers agree that neuroleptic-induced EPS occur in 50% to 75% of patients who take conventional antipsychotics. Atypical antipsychotics were developed to widen the therapeutic index and to reduce EPS. Although the mechanisms are unclear, the risk of EPS is less with the novel antipsychotics than with conventional drugs, and agents that produce low levels of acute EPS are likely to produce less tardive dyskinesia. Nevertheless, clinicians should exercise caution when comparing data from investigations of the novel antipsychotics and, until long-term data become available, should administer the new drags at doses below the EPS-producing level.

UR - http://www.scopus.com/inward/record.url?scp=0031698105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031698105&partnerID=8YFLogxK

M3 - Review article

C2 - 9766616

AN - SCOPUS:0031698105

VL - 59

SP - 23

EP - 27

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 12

ER -